Trial Details
COMPLETEDBasic Information
| Clinical ID | c1140 |
|---|---|
| Identifier | NCT04862741 |
| Trial Title | Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: NX-13 250mg IR|DRUG: NX-13 500mg IR|DRUG: NX-13 500mg MR|DRUG: Placebo |
Participant Information
| Sponsor | Landos Biopharma Inc. |
|---|---|
| City | Huntsville |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE1 |
Time Information
| Start Date | 2021-05-05 |
|---|---|
| Primary Completion Date | 2022-06-17 |
| Completion Date | 2022-10-05 |